Life style and (preventive) health; personal characteristics, 2014-2021
| Characteristics persons | Margins | Periods | Drugs use, 12 years or older Use of cannabis Last month (%) | Drugs use, 12 years or older Use of cannabis Last year (%) | Drugs use, 12 years or older Use of cannabis Ever (%) | Drugs use, 12 years or older Use of drugs, other than cannabis Last month (%) | Drugs use, 12 years or older Use of drugs, other than cannabis Last year (%) | Drugs use, 12 years or older Use of drugs, other than cannabis Ever (%) |
|---|---|---|---|---|---|---|---|---|
| Total | Value | 2014 | . | . | . | . | . | . |
| Total | Value | 2015 | 4.1 | 6.7 | 20.1 | 1.8 | 3.8 | 8.9 |
| Total | Value | 2016 | 3.9 | 6.5 | 19.7 | 1.8 | 4.0 | 9.7 |
| Total | Value | 2017 | 4.5 | 7.1 | 20.6 | 1.6 | 4.1 | 10.0 |
| Total | Value | 2018 | 4.5 | 7.4 | 22.4 | 1.8 | 3.8 | 10.6 |
| Total | Value | 2019 | 4.8 | 7.1 | 21.7 | 2.2 | 4.4 | 11.0 |
| Total | Value | 2020 | 4.9 | 7.7 | 21.8 | 1.6 | 4.5 | 11.8 |
| Total | Value | 2021 | 4.9 | 7.9 | 23.3 | 2.1 | 4.8 | 12.4 |
| Total | Lower boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Total | Lower boundary 95% confidence interval | 2015 | 3.7 | 6.2 | 19.2 | 1.5 | 3.4 | 8.3 |
| Total | Lower boundary 95% confidence interval | 2016 | 3.5 | 5.9 | 18.8 | 1.5 | 3.5 | 9.1 |
| Total | Lower boundary 95% confidence interval | 2017 | 4.0 | 6.5 | 19.8 | 1.3 | 3.6 | 9.4 |
| Total | Lower boundary 95% confidence interval | 2018 | 4.0 | 6.9 | 21.5 | 1.5 | 3.4 | 9.9 |
| Total | Lower boundary 95% confidence interval | 2019 | 4.4 | 6.5 | 20.9 | 1.8 | 4.0 | 10.4 |
| Total | Lower boundary 95% confidence interval | 2020 | 4.4 | 7.1 | 20.8 | 1.4 | 4.1 | 11.0 |
| Total | Lower boundary 95% confidence interval | 2021 | 4.3 | 7.2 | 22.2 | 1.7 | 4.2 | 11.6 |
| Total | Upper boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Total | Upper boundary 95% confidence interval | 2015 | 4.6 | 7.3 | 20.9 | 2.1 | 4.3 | 9.6 |
| Total | Upper boundary 95% confidence interval | 2016 | 4.4 | 7.0 | 20.6 | 2.1 | 4.4 | 10.4 |
| Total | Upper boundary 95% confidence interval | 2017 | 4.9 | 7.6 | 21.5 | 1.9 | 4.5 | 10.6 |
| Total | Upper boundary 95% confidence interval | 2018 | 4.9 | 8.0 | 23.2 | 2.1 | 4.2 | 11.2 |
| Total | Upper boundary 95% confidence interval | 2019 | 5.2 | 7.7 | 22.5 | 2.6 | 4.8 | 11.6 |
| Total | Upper boundary 95% confidence interval | 2020 | 5.4 | 8.3 | 22.7 | 1.9 | 5.0 | 12.5 |
| Total | Upper boundary 95% confidence interval | 2021 | 5.5 | 8.6 | 24.4 | 2.5 | 5.4 | 13.3 |
| Sex: Male | Value | 2014 | . | . | . | . | . | . |
| Sex: Male | Value | 2015 | 6.1 | 9.2 | 24.5 | 2.5 | 5.2 | 11.8 |
| Sex: Male | Value | 2016 | 5.7 | 8.6 | 23.7 | 2.7 | 5.4 | 12.4 |
| Sex: Male | Value | 2017 | 6.5 | 9.4 | 25.1 | 2.1 | 5.1 | 13.0 |
| Sex: Male | Value | 2018 | 6.3 | 10.0 | 27.0 | 2.3 | 4.7 | 13.3 |
| Sex: Male | Value | 2019 | 6.8 | 9.3 | 26.4 | 2.9 | 5.6 | 14.0 |
| Sex: Male | Value | 2020 | 6.9 | 10.1 | 26.1 | 1.7 | 5.1 | 14.7 |
| Sex: Male | Value | 2021 | 7.3 | 10.4 | 28.3 | 2.8 | 5.7 | 15.9 |
| Sex: Male | Lower boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Sex: Male | Lower boundary 95% confidence interval | 2015 | 5.4 | 8.3 | 23.2 | 2.0 | 4.5 | 10.8 |
| Sex: Male | Lower boundary 95% confidence interval | 2016 | 5.0 | 7.7 | 22.3 | 2.1 | 4.7 | 11.4 |
| Sex: Male | Lower boundary 95% confidence interval | 2017 | 5.7 | 8.6 | 23.8 | 1.6 | 4.5 | 12.0 |
| Sex: Male | Lower boundary 95% confidence interval | 2018 | 5.6 | 9.1 | 25.7 | 1.9 | 4.0 | 12.3 |
| Sex: Male | Lower boundary 95% confidence interval | 2019 | 6.0 | 8.5 | 25.0 | 2.3 | 4.8 | 13.0 |
| Sex: Male | Lower boundary 95% confidence interval | 2020 | 6.1 | 9.1 | 24.7 | 1.3 | 4.4 | 13.6 |
| Sex: Male | Lower boundary 95% confidence interval | 2021 | 6.4 | 9.2 | 26.7 | 2.2 | 4.9 | 14.6 |
| Sex: Male | Upper boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Sex: Male | Upper boundary 95% confidence interval | 2015 | 6.9 | 10.1 | 25.8 | 2.9 | 5.9 | 12.8 |
| Sex: Male | Upper boundary 95% confidence interval | 2016 | 6.4 | 9.5 | 25.0 | 3.2 | 6.1 | 13.4 |
| Sex: Male | Upper boundary 95% confidence interval | 2017 | 7.2 | 10.3 | 26.4 | 2.5 | 5.8 | 14.0 |
| Sex: Male | Upper boundary 95% confidence interval | 2018 | 7.0 | 10.9 | 28.3 | 2.7 | 5.3 | 14.3 |
| Sex: Male | Upper boundary 95% confidence interval | 2019 | 7.6 | 10.1 | 27.8 | 3.5 | 6.4 | 15.0 |
| Sex: Male | Upper boundary 95% confidence interval | 2020 | 7.7 | 11.0 | 27.5 | 2.1 | 5.8 | 15.8 |
| Sex: Male | Upper boundary 95% confidence interval | 2021 | 8.4 | 11.6 | 30.0 | 3.5 | 6.7 | 17.3 |
| Sex: Female | Value | 2014 | . | . | . | . | . | . |
| Sex: Female | Value | 2015 | 2.2 | 4.4 | 15.7 | 1.2 | 2.6 | 6.1 |
| Sex: Female | Value | 2016 | 2.2 | 4.4 | 15.9 | 1.0 | 2.6 | 7.1 |
| Sex: Female | Value | 2017 | 2.5 | 4.8 | 16.3 | 1.1 | 3.0 | 7.1 |
| Sex: Female | Value | 2018 | 2.7 | 4.9 | 17.8 | 1.3 | 2.9 | 7.9 |
| Sex: Female | Value | 2019 | 2.8 | 4.8 | 17.0 | 1.4 | 3.2 | 7.9 |
| Sex: Female | Value | 2020 | 2.9 | 5.5 | 17.5 | 1.6 | 4.0 | 8.9 |
| Sex: Female | Value | 2021 | 2.4 | 5.5 | 18.3 | 1.3 | 3.8 | 9.0 |
| Sex: Female | Lower boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Sex: Female | Lower boundary 95% confidence interval | 2015 | 1.7 | 3.7 | 14.6 | 0.8 | 2.1 | 5.4 |
| Sex: Female | Lower boundary 95% confidence interval | 2016 | 1.7 | 3.8 | 14.7 | 0.7 | 2.1 | 6.3 |
| Sex: Female | Lower boundary 95% confidence interval | 2017 | 2.0 | 4.1 | 15.2 | 0.8 | 2.5 | 6.3 |
| Sex: Female | Lower boundary 95% confidence interval | 2018 | 2.2 | 4.2 | 16.7 | 1.0 | 2.4 | 7.1 |
| Sex: Female | Lower boundary 95% confidence interval | 2019 | 2.4 | 4.2 | 15.8 | 1.0 | 2.6 | 7.1 |
| Sex: Female | Lower boundary 95% confidence interval | 2020 | 2.4 | 4.7 | 16.3 | 1.2 | 3.4 | 8.0 |
| Sex: Female | Lower boundary 95% confidence interval | 2021 | 1.9 | 4.7 | 17.0 | 1.0 | 3.2 | 8.0 |
| Sex: Female | Upper boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Sex: Female | Upper boundary 95% confidence interval | 2015 | 2.6 | 5.0 | 16.8 | 1.5 | 3.0 | 6.8 |
| Sex: Female | Upper boundary 95% confidence interval | 2016 | 2.7 | 5.0 | 17.0 | 1.3 | 3.1 | 7.9 |
| Sex: Female | Upper boundary 95% confidence interval | 2017 | 3.0 | 5.4 | 17.4 | 1.5 | 3.5 | 7.9 |
| Sex: Female | Upper boundary 95% confidence interval | 2018 | 3.2 | 5.5 | 18.9 | 1.6 | 3.4 | 8.7 |
| Sex: Female | Upper boundary 95% confidence interval | 2019 | 3.2 | 5.4 | 18.2 | 1.8 | 3.8 | 8.7 |
| Sex: Female | Upper boundary 95% confidence interval | 2020 | 3.4 | 6.2 | 18.7 | 2.0 | 4.6 | 9.8 |
| Sex: Female | Upper boundary 95% confidence interval | 2021 | 3.1 | 6.4 | 19.7 | 1.8 | 4.6 | 10.1 |
| Age: 0 to 3 years | Value | 2014 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2015 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2016 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2017 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2018 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2019 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2020 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2021 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2015 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2016 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2017 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2018 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2019 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2020 | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower boundary 95% confidence interval | 2021 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2014 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2015 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2016 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2017 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2018 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2019 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2020 | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper boundary 95% confidence interval | 2021 | . | . | . | . | . | . |
| Age: 4 to 11 years | Value | 2014 | . | . | . | . | . | . |
| Age: 4 to 11 years | Value | 2015 | . | . | . | . | . | . |
| Age: 4 to 11 years | Value | 2016 | . | . | . | . | . | . |
| Age: 4 to 11 years | Value | 2017 | . | . | . | . | . | . |
| Source: CBS. | ||||||||
Dataset is not available.
This table contains data on life style and on the (preventive) health examination of the Dutch population in private households. These data can be grouped by several personal characteristics.
Data available from: 2014-2021
Status of the data: final.
Changes by July 31, 2023
None, the table has been discontinued.
When will new data be published?
Not applicable anymore. This table has been replaced, see paragraph 3 for a link to the new table.
Description topics
- Drugs use, 12 years or older
- The questions on the use of drugs are asked to persons aged twelve years or older. For the following types of drugs, it is asked whether people have ever used it and if so, when for the last time:
Cannabis (hashish, weed, marijuana)
Amphetamine (such as pep and speed)
XTC (ecstasy, MDMA)
LSD
Mushrooms (hallucinogenic mushrooms, magic mushrooms)
Cocaine (including crack, basecoke, freebase)
Heroine (horse, smack, or brown)
GHB
Methadone
From 2018: 4-Fluoramphetamine, also known as 4-FA, 4-FMP or Flux
Other drugs
The answer categories for each type of drug are:
Yes, in the last 30 days
Yes, in the last 12 months, but not in the last 30 days
Yes, more than 12 months ago
No, never used- Use of cannabis
- Based on the question about the use of cannabis (hashish, weed, marijuana)
- Last month
- Last year
- Ever
- Use of drugs, other than cannabis
- Based on the question about the use of:
• Amphetamine (such as pep and speed)
• XTC (ecstasy, MDMA)
• LSD
• Mushrooms (hallucinogenic mushrooms, magic mushrooms)
• Cocaine (including crack, cooked coke, freebase)
• Heroine (horse, smack or brown)
• GHB
• Methadone
• From 2018: 4-Fluoramphetamine, also known as 4-FA, 4-FMP or Flux
• Other drugs
This concerns the use of one or more of these types of drugs. When several of these drugs are used, the most recently used drug type determines which of the answer categories ‘last month’, ‘last year’ and ‘ever’ applies.- Last month
- Last year
- Ever